GlassScriptPhysician profile
Sara J Young
NPI 1992220552
$4,779.12
in general payments reported to CMS, 2019-2025
32 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $75.77 · 2023: $1,375 · 2024: $2,095 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,071 · Travel and Lodging: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,070.90 |
| Travel and Lodging | $513.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,081.80 | 2021-2023 | Watchman Access System, Wolverine Coronary Cutting Balloon |
| Alnylam Pharmaceuticals INC. | $633.82 | 2023-2025 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $431.15 | 2024-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $353.05 | 2023-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $328.26 | 2024-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.33 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $205.09 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $148.45 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $133.42 | 2023-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $101.20 | 2024-2025 | |
| Pfizer INC. | $96.28 | 2023-2025 | |
| Amgen INC. | $84.40 | 2024-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $82.31 | 2023-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $80.75 | 2023-2024 | Inpefa |
| Abbott Laboratories | $70.33 | 2024-2025 | Optis, Thoratec Heartmate 3 Lvas Implant Kit, Perclose Prostyle |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $60.11 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $57.57 | 2021-2023 | Micra |
| Actelion Pharmaceuticals US, INC. | $55.71 | 2024 | Uptravi, Opsumit |
| Bridgebio Pharma, INC. | $52.15 | 2025 | Attruby |
| Teleflex LLC | $49.70 | 2022-2023 | Langston |
| Shockwave Medical, INC | $45.82 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $45.59 | 2024 | Wegovy |
| Cardiva Medical, INC. | $44.37 | 2022-2024 | Optowire |
| Chiesi USA, INC. | $37.38 | 2023-2025 | Cleviprex, Kengreal, Juxtapid |
| Abiomed | $36.86 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $34.17 | 2024 | Arcalyst |
| Abbvie INC. | $30.72 | 2023 | |
| Davol INC. | $22.81 | 2025 | Arista |
| Cordis US Corp. | $19.37 | 2024 | Mynxgrip |
| Heartflow, INC. | $19.27 | 2025 | |
| Esperion Therapeutics, INC. | $15.59 | 2024 | Nexletol |
| Biotronik INC. | $14.29 | 2023 | Biomonitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.